|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.69 USD | +1.31% |
|
+3.29% | +5.11% |
| Apr. 23 | JPMorgan Adjusts Price Target on Janus Henderson to $35 From $31, Maintains Neutral Rating | MT |
| Apr. 12 | UBS Adjusts Janus Henderson Group Price Target to $30 From $28, Maintains Sell Rating | MT |
Artiva Biotherapeutics, Inc. announced that it will issue 10,909,091 series B Preferred shares at an issue price of $11 per share for gross proceeds of $120,000,001 in funding on February 19, 2021. The shares are convertible and non-redeemable. The shares are convertible into equity shares at an fixed conversion price of $11 per share.
The company will issue securities pursuant to exemption provided under Regulation D.
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 37,600 KRW | +0.53% | +4.16% | 410M | ||
| 15,270 KRW | +0.13% | +0.86% | 506M | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +5.11% | 5.11B | |
| -6.03% | 113B | |
| -3.98% | 87.91B | |
| +20.42% | 63.85B | |
| +5.29% | 61.9B | |
| +10.12% | 42.86B | |
| +7.95% | 40.84B | |
| +18.92% | 34.58B | |
| +5.88% | 25.46B | |
| -5.25% | 22.13B |
JANUS HENDERSON GROUP PLC 
